(Total Views: 220)
Posted On: 09/06/2019 7:26:43 PM
Post# of 281
NetworkNewsBreaks – Why Predictive Oncology Inc. (NASDAQ: POAI) Is ‘One to Watch’
Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. A recent article discussing the company reads, “Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. . . . In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM) patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. A recent article discussing the company reads, “Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. . . . In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM) patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
